$ADMA

Adma Biologics Inc

  • NASDAQ/NMS (GLOBAL MARKET)
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$1.56 ▲0.645%

Extented Hours

VOLUME

644,036

DAY RANGE

1.55 - 1.61

52 WEEK

1.38 - 3.71

Join Discuss about ADMA with like-minded investors

profile
@Math #StockTraders.NET
recently

$RIBT $MVIS $ADMA main winners today

149 Replies 15 👍 6 🔥

profile
@TradesbytheBell #Trades by the Bell LLC
recently

@everyone Day Trade Exit

93 Replies 14 👍 15 🔥

profile
@TradesbytheBell #Trades by the Bell LLC
recently

@everyone Day Trade

58 Replies 14 👍 6 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $MVIS, $OCGN, $SKLZ, $ADMA

81 Replies 10 👍 14 🔥

profile
@TraderXx #StockTraders.NET
recently

$ADMA $SONN yes please

147 Replies 7 👍 9 🔥

profile
@DHouse #StockTraders.NET
recently

adma could have a little breakout after consolidating

144 Replies 6 👍 10 🔥

profile
@Neptune5045 #StockTraders.NET
recently

Also $KZIA $ADMA worth watching > @Neptune5045 said: $SONN $LMNL $KMDA familiar names

92 Replies 6 👍 7 🔥

Key Metrics

Market Cap

198.69 M

Beta

0.60

Avg. Volume

1.80 M

Shares Outstanding

128.19 M

Yield

0%

Public Float

0

Next Earnings Date

2021-08-04

Next Dividend Date

Company Information

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.

Website:

HQ: ,

Related News

  • Stock Equity

    Bright Stock Buzz: ADMA Biologics, Inc. (NASDAQ:ADMA), ContraFect Corporation (NASDAQ:CFRX)

    28 Jul 2021, 23:10
  • Stock Equity

    Traders should take notice on: ADMA Biologics, Inc. (NASDAQ:ADMA), Alcoa Corporation (NYSE:AA)

    26 Jul 2021, 23:09
  • Stock Equity

    Comprehensive Stock Analysis: Tencent Music Entertainment Group (NYSE:TME), ADMA Biologics, Inc. (NASDAQ:ADMA)

    24 Jul 2021, 00:17
  • Intrado Digital Media

    ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

    20 Jul 2021, 11:00
  • Stock Equity

    Traders cant mares this Stock: ADMA Biologics, Inc. (NASDAQ:ADMA), Gold Fields Limited (NYSE:GFI)

    18 Jul 2021, 23:05